Marcela V. Maus, M.d.,ph.d.

This is a first-in-human study testing a new cell therapy called CARv3-TEAM-E for glioblastoma, an aggressive brain cancer. Researchers will collect a patient's own immune cells, genetically modify them to target cancer, and reinfuse them to see if they can safely fight the tumor…

This is a first-in-human study testing a new type of personalized immune cell therapy (CAR-T cells) for adults with Non-Hodgkin Lymphoma that has come back or stopped responding to standard treatments. The main goal is to find a safe dose of these modified immune cells, which are…

This early-stage trial is testing a new type of CAR T-cell therapy called TriPRIL for adults with multiple myeloma that has returned or stopped responding to standard treatments. Researchers will give patients a single infusion of their own modified immune cells to try to fight t…

This study is testing whether a drug called emapalumab can prevent severe side effects that sometimes occur with CAR-T cell therapy, a powerful treatment for certain lymphomas. Researchers will give emapalumab to 28 adults with hard-to-treat lymphoma who are receiving CAR-T thera…

This study follows 45 adults who previously received CAR-T cell therapy in earlier cancer trials. Researchers will track their health for up to 15 years to monitor long-term safety, check if the treatment remains effective, and watch for any delayed side effects. No new treatment…